Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Plummer

Showing results (101-110 of 161) with videos related to

Pageof 17
Sort By:
Cancer Treatment Reviews|September 3, 2025
Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to actionWinette T A van der Graaf, Nina S Heiss, Carolyn L Hynes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2009
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumorsRuth Plummer, Laura Vidal, Melanie Griffin, et al.
Oncoimmunology|June 7, 2018
Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trialPoulam M Patel, Christian H Ottensmeier, Clive Mulatero, et al.
Clinical Therapeutics|October 18, 2016
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label StudiesLuc Dirix, Helen Swaisland, Henk M W Verheul, et al.
BMC Cancer|July 2, 2021
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanomaOliver Coen, Pippa Corrie, Helen Marshall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2021
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Erica De Zan, Mustafa Elshani, et al.
NPJ Breast Cancer|April 8, 2022
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancerMelinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, et al.
The New England Journal of Medicine|September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Axel Hauschild, Mario Santinami, et al.
Cell Reports. Medicine|June 18, 2025
A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastomaJuanita Suzanne Lopez, Simon Haefliger, Ruth Plummer, et al.
Blood Advances|May 24, 2018
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductaseSarah E Fordham, Helen J Blair, Claire J Elstob, et al.
Pageof 17

Showing results (101-110 of 161) with videos related to

Sort By:
Pageof 17
Cancer Treatment Reviews|September 3, 2025
Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to actionWinette T A van der Graaf, Nina S Heiss, Carolyn L Hynes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2009
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumorsRuth Plummer, Laura Vidal, Melanie Griffin, et al.
Oncoimmunology|June 7, 2018
Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trialPoulam M Patel, Christian H Ottensmeier, Clive Mulatero, et al.
Clinical Therapeutics|October 18, 2016
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label StudiesLuc Dirix, Helen Swaisland, Henk M W Verheul, et al.
BMC Cancer|July 2, 2021
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanomaOliver Coen, Pippa Corrie, Helen Marshall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2021
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Erica De Zan, Mustafa Elshani, et al.
NPJ Breast Cancer|April 8, 2022
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancerMelinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, et al.
The New England Journal of Medicine|September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Axel Hauschild, Mario Santinami, et al.
Cell Reports. Medicine|June 18, 2025
A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastomaJuanita Suzanne Lopez, Simon Haefliger, Ruth Plummer, et al.
Blood Advances|May 24, 2018
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductaseSarah E Fordham, Helen J Blair, Claire J Elstob, et al.
Pageof 17